Physician profile
Thomas E Steffen
NPI 1083619092
$3,272.71
in general payments reported to CMS, 2019-2025
43 companies · $480 in 2025
The $480 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $210 · 2021: $582 · 2022: $705 · 2023: $639 · 2024: $530 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,648.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $450.15 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $339.12 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $281.17 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.27 | 2021-2025 | Jardiance |
| Abbott Laboratories | $210.44 | 2023-2025 | Aveir, Assurity, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $204.26 | 2019-2023 | Farxiga |
| Astellas Pharma US INC | $168.55 | 2019-2025 | Veozah |
| Antares Pharma, INC. | $131.62 | 2022-2025 | Xyosted |
| Abbvie INC. | $113.30 | 2022-2025 | Vraylar |
| Phathom Pharmaceuticals, INC. | $89.33 | 2024-2025 | Voquezna |
| Dexcom, INC. | $85.15 | 2020-2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $73.06 | 2020-2022 | |
| Sanofi Pasteur INC. | $72.29 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $63.56 | 2020-2022 | |
| Boston Scientific Corporation | $58.50 | 2025 | Wavewriter Alpha Prime 16 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Steffen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.